Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-Ascorbic Acid in AML and MDS
NCT00329498Phase 2Suspended
- Sponsor
- Samsung Medical Center
- Start
- May 1998
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ascorbic acid in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Samsung Medical Center. Primary endpoints: Efficacy and Clinical Safety. Started May 1998; status: suspended.
02
Drugs
ascorbic acid
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00329498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00329498.